Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

The dose-dense delivery of chemotherapy (greater frequency of drug delivery) was explored in women with advanced ovarian cancer. All patients received carboplatin; half received paclitaxel weekly and half every 3 weeks. There were no between-group differences in progression-free survival. Ovarian ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 374; číslo 8; s. 738 - 748
Hlavní autoři: Chan, John K, Brady, Mark F, Penson, Richard T, Huang, Helen, Birrer, Michael J, Walker, Joan L, DiSilvestro, Paul A, Rubin, Stephen C, Martin, Lainie P, Davidson, Susan A, Huh, Warner K, O’Malley, David M, Boente, Matthew P, Michael, Helen, Monk, Bradley J
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 25.02.2016
Témata:
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bevacizumab
Bevacizumab - administration & dosage
Carboplatin
Carboplatin - administration & dosage
Chemotherapy
Clinical outcomes
Disease-Free Survival
Drug Administration Schedule
Drug delivery
Drug dosages
Female
Humans
Infusions, Intravenous
Intention to Treat Analysis
Middle Aged
Monoclonal antibodies
Motivation
Neuropathy
Neutropenia
Ovarian cancer
Ovarian Neoplasms - drug therapy
Paclitaxel
Paclitaxel - administration & dosage
Patients
Survival
Targeted cancer therapy
United States > US
California
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The dose-dense delivery of chemotherapy (greater frequency of drug delivery) was explored in women with advanced ovarian cancer. All patients received carboplatin; half received paclitaxel weekly and half every 3 weeks. There were no between-group differences in progression-free survival. Ovarian cancer, the most lethal gynecologic cancer, is responsible for approximately 14,000 deaths in the United States annually. 1 The incorporation of bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in the treatment regimen prolongs progression-free survival but not overall survival. 2 – 5 A dose-dense regimen of paclitaxel involving greater frequency of drug delivery may enhance its antineoplastic effect by eliciting antiangiogenic and proapoptotic properties. 6 – 9 Weekly paclitaxel therapy prolonged survival among patients with early-stage breast cancer and those with metastatic breast cancer. 10 , 11 In a study involving patients with ovarian cancer, Japanese investigators found that dose-dense weekly paclitaxel prolonged progression-free . . .
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
The authors’ full names, academic degrees, and affiliations are listed in the Appendix.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1505067